Netupitant/palonosetron

From WikiProjectMed
Jump to navigation Jump to search

Netupitant/palonosetron
Combination of
NetupitantNK1 receptor antagonist
Palonosetron5-HT3 receptor antagonist
Names
Trade namesAkynzeo
Clinical data
Main usesChemotherapy-induced nausea and vomiting[1]
Side effectsHeadache, constipation, tiredness[2]
Pregnancy
category
Routes of
use		By mouth, intravenous
External links
AHFS/Drugs.comMonograph
US NLMNetupitant/palonosetron
MedlinePlusa614053
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) [5]
  • US: ℞-only [6]
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)

Netupitant/palonosetron, sold under the brand name Akynzeo, is a combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.[1] It is taken by mouth.[1] It is used with dexamethasone.[1]

Common side effects include headache, constipation, and tiredness.[2] The dose does not need to be adjusted in those with mild to moderate liver or kidney problems.[1] Use is not recommended in pregnancy.[7] Netupitant is an NK1 receptor blocker and palonosetron is a 5-HT3 receptor blocker.[2]

The combination was approved for medical use in the United States in 2014 and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £70 a dose as of 2021.[7] In the United States this amount costs about 680 USD.[8]

Medical use

Dosage

The typical dose is one capsule a hour before chemotherapy.[2] This contains 300 mg of netupitant and 0.5 mg of palonosetron.[1]

There is an intravenous version that contains fosnetupitant and palonosetron.[9][6]

Contraindications

Netupitant/palonosetron may be contraindicated during pregnancy.[10][3][4]

Side effects

The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness.[6] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[10]

Interactions

Further information: Netupitant § Interactions, and Palonosetron § Interactions

Pharmacology

Further information: Netupitant § Pharmacology, and Palonosetron § Pharmacology

History

Netupitant/palonosetron was approved for use in the United States in October 2014.[11] It was approved for use in the European Union in May 2015.[2] The intravenous version was approved in the United States in April 2018.[12][9]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Netupitant/Palonosetron Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 12 November 2021.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
  3. ↑ 3.0 3.1 3.2 "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 December 2019. Retrieved 19 March 2020.
  4. ↑ 4.0 4.1 "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
  5. ↑ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
  6. ↑ 6.0 6.1 6.2 "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
  7. ↑ 7.0 7.1 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 456. ISBN 978-0857114105.
  8. ↑ "Akynzeo Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 12 November 2021.
  9. ↑ 9.0 9.1 "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Archived from the original on 24 January 2020. Retrieved 19 March 2020.
  10. ↑ 10.0 10.1 Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.{{cite book}}: CS1 maint: unrecognized language (link)
  11. ↑ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
  12. ↑ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.

External links

Identifiers:
Retrieved from "https://mdwiki.org/w/index.php?title=Netupitant/palonosetron&oldid=1290805"